Click on a filter below to refine your search. Remove a filter to broaden your search.
Novel fracture differences were seen within Asian subgroups.
Updated shots to shield against COVID-19 infection were approved by the US Food and Drug Administration on Thursday.
The risks for all-cause mortality, adverse cardiovascular events, acute kidney injury and adverse kidney events were lower versus GLP-1 RA.
41.9% of patients had resolution within three years of diagnosis, with a median time to resolution of 1.9 years.
The number of deaths from COVID-19 was 68.9% lower than in 2022.
Lower levels of trust were tied to significantly lower odds of COVID-19 and flu vaccination.
The findings show a benefit even among those at high genetic risk for diabetes.
The findings were seen in a large study of older veterans with diabetes.
No meaningful differences in mean laboratory values were seen between those with a PASC index of 12 or higher versus 0.
Additional benefits include improved kidney and heart health in patients with hypertension.